Amgen (NASDAQ:AMGN) CFO A Kelly Michael sold 2,065 shares of Amgen stock on the open market in a transaction dated Monday, April 28th. The stock was sold at an average price of $110.45, for a total value of $228,079.25. Following the sale, the chief financial officer now directly owns 41,041 shares in the company, valued at approximately $4,532,978. Amgen, Inc. (NASDAQ:AMGN) shares after opening at $112.30 moved to $112.45 on last trade day and at the end of the day closed at $111.90. Company price to sales ratio in past twelve months was calculated as 4.47 and price to cash ratio as 4.28. Amgen, Inc. (NASDAQ:AMGN) showed a negative weekly performance of -6.20%.
Chimerix (NASDAQ:CMRX) Insider Timothy W. Trost sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $18.67, for a total transaction of $93,350.00. Following the completion of the sale, the insider now directly owns 629 shares in the company, valued at approximately $11,743. Chimerix Inc. (NASDAQ:CMRX) shares fell -0.54% in last trading session and ended the day on $18.58. CMRX return on equity ratio is recorded as -157.50% and its return on assets is -73.10%. Chimerix Inc. (NASDAQ:CMRX) yearly performance is -2.31%.
Portola Pharmaceuticals (NASDAQ:PTLA) CFO Mardi Dier sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $24.14, for a total value of $120,700.00. Following the sale, the chief financial officer now directly owns 24,824 shares of the company’s stock, valued at approximately $599,251.
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) shares moved up 1.69% in last trading session and was closed at $23.41, while trading in range of $22.43 – $24.15. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) year to date (YTD) performance is -9.09%.
Stemline Therapeutics (NASDAQ:STML) Insider Eric K. Rowinsky sold 11,179 shares of the stock on the open market in a transaction dated Friday, April 25th. The stock was sold at an average price of $15.03, for a total transaction of $168,020.37. Following the completion of the sale, the insider now directly owns 131,773 shares of the company’s stock, valued at approximately $1,980,548. Stemline Therapeutics Inc. (NASDAQ:STML) weekly performance is -8.51%. On last trading day company shares ended up $15.26. Stemline Therapeutics Inc. (NASDAQ:STML) distance from 50-day simple moving average (SMA50) is -30.47%. Analysts mean target price for the company is $57.00.